Notre Dame Faculty from the Departments of Chemistry & Biochemistry and Biological Sciences have been awarded a grant from the Indiana Clinical and Translational Sciences Institute (CTSI).
Bradley Smith, Emil T. Hofman Professor of Chemistry & Biochemistry and a researcher in the Warren Family Research Center for Drug Discovery and Development…
Notre Dame's Richard Taylor, Interim Director of the Warren Family Research Center for Drug Discovery and Development and Professor of Chemistry & Biochemistry has been selected to participate in a National Institutes of Health training program, “Neurotherapeutics Discovery and Development for Academic Scientists
…
One bacterial pathogen is responsible for a range of diseases, from pharyngitis and impetigo to more severe diagnoses such as toxic shock syndrome and necrotizing fasciitis (flesh eating disease), a serious bacterial skin infection that spreads quickly and kills the body’s soft tissue. The pathogen, known as Group A Streptococcus, remains a global health burden with an estimated 700 million cases reported annually, and more than half a million deaths due to severe infections.
University of Notre Dame researchers have discovered a compound that accelerates diabetic wound healing, which may open the door to new treatment strategies.
Faculty researchers with an interest in the drug discovery process from across the University are invited to apply to spend a period of at least two to three months embedded within the chemistry program at Eli Lilly & Co. in Indianapolis, Indiana.
…
The Warren Family Research Center for Drug Discovery and Development at the University of Notre Dame has established a research collaboration with Retrophin, Inc. and the Grace Wilsey Foundation to focus on developing treatment for NGLY1 deficiency. …
A common critical gap in commercialization of technologies originating from the academic labs is the funding necessary to develop a robust commercialization relevant data package to reduce the risk of investment in early stage technologies. The Indiana CTSI and Indiana University School of Medicine through the office of the Associate Dean for Entrepreneurship and its Industry Collaboration Portal (ICP), are partnering with the newly created Indiana Center for Biomedical Innovation (ICBI) at IU Health to help fill this critical gap through a new support program, Technology Enhancement Awards (TEA), for early stage technologies. The technology may already reside in a start-up company or a clear plan exists to place it into a start-up. The New Program will partner with the highly successful SPARK program at Stanford University.…
SUBMISSION DEADLINE: October 15, 2015
The Molecular Therapeutics Program, a part of the Indiana Clinical and Translational Sciences Institute, has established a service agreement with Covance, Inc. to support early-stage drug discovery within CTSI partners: Indiana University, Purdue University, and the University of Notre Dame. The Molecular Therapeutic Program (MTP) will support early-stage drug development studies through services provided by Covance Inc. and Quintiles Biosciences, two contract research organizations that provide pharmaceutical development services. Small grants are now available to help support a list of services available: …
Robert V. Stahelin, Ph. D., associate professor of biochemistry and molecular biology at Indiana University School of Medicine-South Bend (IUSM-SB), adjunct faculty in the Department of Chemistry & Biochemistry has been awarded the Navari Family Endowed Chair…
WFRCDD Investigators and Professors of Chemistry & Biochemistry Paul Helquist and Olaf Wiest have been awarded a $100,000 grant from the Ara Parseghian Medical Research Foundation for "Design and Synthesis of Small Molecule Agents for Studies and Treatment of NPC Disease". Much of the work, which includes a group of international collaborators, will be carried out in the Chemical Synthesis and Drug Discovery Facility.…
June is Alzheimer’s and Brain Awareness Month, which seemed a particularly apt time to talk with Rich Taylor, a University of Notre Dame researcher whose research focuses on the discovery and development of new therapeutic leads for the treatment of unmet clinical needs in a number of diseases, including Alzheimer’s. Taylor is associate vice president for research, professor of chemistry and biochemistry and interim director of the Warren Family Research Center for Drug Discovery and Development.
The Community forOpen Antimicrobial Drug Discovery (CO-ADD) is a Wellcome Trust funded, non-for-profit, openframework for discovery and development of new therapies against multidrug-resistant (MDR) bacteria (www.co-add.org) based at The University of Queensland in Australia.
CO-ADD will perform primary antibacterial screening for academic research groups as a free service and makes no claims on results or IP.…
Rich Taylor, a member of the University of Notre Dame faculty since 1995, is a professor of chemistry and biochemistry in the College of Science. Taylor, who also serves as associate vice president for research at the University, has recently been appointed as interim director of the Warren Family Research Center for Drug Discovery and Development. Read more...
Seed funding, up to $10,000, and advice is available for researchers seeking to develop early stage drug discovery projects.
SUBMISSION DEADLINE - July 1, 2015
The Molecular Therapeutics Program, a part of the Indiana Clinical and Translational Sciences Institute, seeks applications for a competitive program that will provide funds and essential consultation to support the early stage development of therapeutics. This opportunity is provided in concert with the newly established Indiana Drug Discovery Alliance (IDDA), a clearinghouse for drug discovery and development resources at the Indiana-CTSI member institutions of Indiana University, Purdue University and the University of Notre Dame.
Warren Family Center initiated the creation of an international team of researchers focused on the search for small molecule therapeutics for NGLY1 deficiency in collaboration with the Grace Wilsey Foundation.…
University of Notre Dame researchers led an international team to identify a molecular mechanism responsible for making malaria parasites resistant to artemisinins, the leading class of antimalarial drugs.
According to the World Health Organization’s 2014 World Malaria Report, there are an estimated 198 million cases of malaria worldwide with 3.3 billion people at risk for contracting the infection. Although the impact of malaria is still significant, the statistics reflect a considerable reduction in the global malaria burden. Since 2010, disease transmission has been reduced by 30 percent and mortality due to malaria has decreased by almost half.
Warren Family Center hosted a visitors from Novartis Pharmaceutical Corporation including Susan Giacalone (Area Scientific Associate Director- Field Medical MSL, Rare Diseases), Julio Fernandez (Field Medical National Director, Rare Diseases), John Murry, (Regional Scientific Director), Beth Ostergard Stillwell (Oncology Regional Scientific Director).…
Warren Family Center hosted a visit from Eli Lilly President and CEO, Dr. John Lechleiter and Senior Director, Dr. Jay McGill.…
Warren Family Center researcher Paul Helquist attends the Grace Wilsey Foundation’s Inaugural Scientific Conference.
Estimates of deaths from methicillin-resistant Staphylococcus aureus (MRSA) in the United States range upwards of 19,000 annually. Around 1960, when Staphylococcus aureus developed resistance to first-generation penicillin, methicillin and other second-generation beta-lactam antibiotics were adopted to fight the illness. The modern variants of the bacterium have developed resistance to the four drugs now used to treat it.
A team of researchers led by Shahriar Mobashery and Mayland Chang at the University of Notre Dame has discovered a promising new antibiotic, a vital weapon against disease as pathogens evolve to develop resistance to long-used drugs.